Vaginal microbiome seeding and health outcomes in Cesarean-delivered neonates: a randomized controlled trial

在2023财年，临床试验在因新冠肺炎暂停2年后继续招募。许多母亲已经登记并被随机分组，婴儿被跟踪到3岁以下，并使用系列数据和样本采集点进行跟踪。对治疗臂之间最初的早期生命微生物组数据进行了分析，结果表明，治疗臂之间在微生物组结构和组成上存在差异，阴道播种导致母亲的微生物组植入多个婴儿身体部位。阴道播种的动物模型已经开始，以获得进一步的机械洞察。

During the Fiscal Year 2023, the clinical trial continued enrollment after a 2 year pause due to Covid-19. Many mothers have been enrolled and randomized, with infants being followed up to 3 years of age with serial data and sample collection points. Initial early life microbiome data between treatment arms has been analyzed and shows a difference in microbiome structure and composition between treatment arms and that vaginal seeding causes engraftment of the maternal microbiome in multiple infant body sites. Animal models of vaginal seeding to gain further mechanistic insight have commenced.